Loading clinical trials...
Loading clinical trials...
An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19
Conditions
Interventions
MVA-SARS-2-S vaccinations (days 0 & 28)
Comirnaty
Locations
1
Germany
CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Start Date
October 5, 2020
Primary Completion Date
August 24, 2021
Completion Date
August 24, 2021
Last Updated
November 5, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions